King's College London

Research portal

Angiogenic MicroRNAs Linked to Incidence and Progression of Diabetic Retinopathy in Type 1 Diabetes

Research output: Contribution to journalArticle

Anna Zampetaki, Peter Willeit, Simon Jonathan Burr, Xiaoke Yin, Sarah Raye Langley, Stefan Kiechl, Ronald Klein, Peter Rossing, Nishi Chaturvedi, Manuel Mayr

Original languageEnglish
Pages (from-to)216-27
Number of pages11
JournalDiabetes
Volume65
Issue number1
Early online date22 Sep 2015
DOIs
Publication statusPublished - Jan 2016

Documents

King's Authors

Abstract

Circulating microRNAs (miRNAs) have emerged as novel biomarkers of diabetes. The present study focuses on the role of circulating miRNAs in patients with type 1 diabetes and their association with diabetic retinopathy. A total of 29 miRNAs were quantified in serum samples (n=300) using a nested case-control study design in two prospective cohorts of the Diabetic Retinopathy Candesartan Trial (DIRECT programme): PROTECT-1 and PREVENT-1. The PREVENT-1 trial included patients without retinopathy at baseline; the PROTECT-1 trial included patients with non-proliferative retinopathy at baseline. Two miRNAs previously implicated in angiogenesis, miR-27b and miR-320a, were associated with incidence and with progression of retinopathy: the odds ratio per standard deviation higher miR-27b was 0.57 (95%CI: 0.40, 0.82; P=0.002) in PREVENT-1, 0.78 (0.57, 1.07; P=0.124) in PROTECT-1, and 0.67 (0.50, 0.92; P=0.012) combined. The respective odds ratios for miR-320a were 1.57 (1.07, 2.31; P=0.020), 1.43 (1.05, 1.94; P=0.021), and 1.48 (1.17, 1.88; P=0.001). Proteomics analyses in endothelial cells returned the anti-angiogenic protein thrombospondin-1 as a common target of both miRNAs. Our study identifies two angiogenic miRNAs, miR-320a and miR-27b, as potential biomarkers for diabetic retinopathy.

Download statistics

No data available

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454